In: Atkinson P, Glasner P, Lock M (eds) Handbook of genetics and

In: Atkinson P, Glasner P, Lock M (eds) Handbook of genetics and society. Routledge, London, pp 41–58 Wehling M (2008) Translational medicine: science or wishful thinking? J Transl Med 6:31PubMedCrossRef Wehling M (2010) Principles of translational science in medicine. Cambridge University Press, Cambridge Weissmann G (2005) Roadmaps, translational research, and childish curiosity. FASEB J 19:1761–1762PubMedCrossRef Williams RJ, Walker I, Takle AK (2012) Collaborative approaches to anticancer drug discovery and development: a cancer research UK perspective. Drug Discov Today 17:185–187PubMedCrossRef

Wilson-Kovacs DM, Hauskeller C (2012) The clinician-scientist: professional dynamics in clinical stem cell A-1210477 research buy research. Sociol Health Trichostatin A solubility dmso Illn 34(4):497–512PubMedCrossRef

Wissenschaftsrat (1986) Empfehlungen zur klinischen Forschung in den Hochschulen. Wissenschaftsrat, Köln Wissenschaftsrat (2004) Empfehlungen zu forschungs- und lehr-förderlichen Strukturen in der Universitätsmedizin. Wissenschaftsrat, Köln Wissenschaftsrat (2010) Empfehlungen zur Weiterentwicklung der ambulanten Universitätsmedizin in Deutschland. Wissenschaftsrat, Köln Woolf SH (2008) The Cell Cycle inhibitor meaning of translational research and why it matters. JAMA 2999(2):211–213CrossRef Yap TA, Sandhu SK, Workman P, de Bono JS (2010) Envisioning the future of early anticancer drug development. Nat Rev Cancer 10:514–523PubMedCrossRef Zerhouni

EA (2005) Translational and clinical science—time for a new vision. N Engl J Med 353:1621–1623PubMedCrossRef”
“Introduction—the context of pregnancy, childbirth and neonatal screening Newborn metabolic screening is a distinct subset of the varied screenings that are available in the prenatal and neonatal period. Maternity care revolves around many screens for maternal infections, blood pressure, gestational diabetes, fetal abnormalities and other risks to the mother and fetus. The identification of such risks permits a range of interventions to prevent serious health problems for mother and baby throughout the pregnancy and birth process. Furthermore, after birth there are screening options for MG-132 hearing loss (White et al. 1994; Yoshinaga-Itano 2004), metabolic diseases (Garg and Dasouki 2006; Yoon et al. 2005) and other physical disorders (Fisher 1991; Pass et al. 2000; Quinn et al. 1977). Public health screening programmes are rare occurrences in maternity care, with non-programme screening being a more common practice. Referred to as ‘opportunistic screening’ or ‘standard medical practice’, the health professional evaluates and tailors the tests to the patient’s individual circumstances.

Comments are closed.